#DYK Elevated tau in cerebral spinal fluid (CSF) is a hallmark of patients with neurodegenerative disease and severe head injuries, suggesting its role as a biomarker with specificity for brain injury. Research also suggests p-Tau 181 is more strongly associated with Alzheimer’s disease markers than total tau. By measuring phosphorylated tau protein levels in the blood, researchers can gain insights into the role of ptau-181 in the disease process and develop new diagnostics and neuro-prognostics for these debilitating diseases. Advance your neurology research from discovery to the clinic and learn more about the applications of p-tau 181 ➡️ https://bit.ly/3V0cNpa #Alzheimers #ptau181 #neurology #clinicalresearch
Quanterix’s Post
More Relevant Posts
-
How are blood-based biomarkers (BBMs) making an impact on Alzheimer’s disease detection? Eisai’s Kathryn Kern Jamison, PhD, and Daryl Rhys Jones, PhD, joined Associate Professor of Neurology at Washington University in St. Louis Suzanne Schindler, MD, PhD, to co-author a Nature Magazine Milestones feature on the importance of accurate, early diagnosis in the era of anti-amyloid therapies. Read it here: https://lnkd.in/gGrxWsfT #AlzheimersDisease #neurology
To view or add a comment, sign in
-
Engaging neuroscientist with 12+ years of experience in CNS and ocular diseases interested in Medical Science Liaison or related positions in Medical Affairs.
Alzheimer’s research has moved forward in the recent years with 2 drugs (not considering Biogen’s Aduhelm) currently in market- Eisai’s Leqembi (lecanemab) and the other being Eli Liley’s Donanemab (Kinsula). Previously, the disease could only be confirmed in postmortem brains by the presence of amyloid plaques and tau neurofibrillary tangles, making it difficult for a confirmed diagnosis since cognitive impairment can have many causes. Now, amyloid deposition, toxic tau and neurodegeneration can be detected by imaging and/or fluid biomarkers. Among the different methods of detection, the blood based method is more acceptable to patients, does not require any specialized equipment or training, and is lower in cost compared to amyloid or tau PET scan and CSF testing of biomarkers through lumbar puncture. FDA’s approval of blood based biomarkers in Alzheimer’s disease diagnosis holds promise not only in early disease diagnosis but treatment too.
How are blood-based biomarkers (BBMs) making an impact on Alzheimer’s disease detection? Eisai’s Kathryn Kern Jamison, PhD, and Daryl Rhys Jones, PhD, joined Associate Professor of Neurology at Washington University in St. Louis Suzanne Schindler, MD, PhD, to co-author a Nature Magazine Milestones feature on the importance of accurate, early diagnosis in the era of anti-amyloid therapies. Read it here: https://lnkd.in/gGrxWsfT #AlzheimersDisease #neurology
Blood tests for Alzheimer’s disease in the era of anti-amyloid therapies
To view or add a comment, sign in
-
ATTENTION HEALTHCARE PROVIDERS: Dr. Frederick R. Carrick, Professor of Neurology at the University of Central Florida - College of Medicine, will present at the Handelshøyskolen BI in Olso, Norway, on June 1, 2024. The presentation, entitled “Discussion of Recent Published Research on Wound Healing and Parkinson’s Disease,” will discuss ongoing research into therapies, such as those developed by Gladiator Therapeutics, for neurodegenerative disorders and present investigations and human trials. This will be an exciting and current interactive presentation with time reserved for questions and answers. Learn more here. https://ow.ly/IJcI50RpFYJ #GladiatorTherapeutics #DrFrederickCarrick #UniversityOfCentralFlorida #Neurology #BISchoolOfBusiness #Norway #EmergingTherapies #FarInfrared #StemCell #WoundHealing #ParkinsonsDisease #Parkinsons
To view or add a comment, sign in
-
Simoa® Neurology 4-Plex D (N4PD) Advantage PLUS Assay is empowering breakthroughs in neurology research 🧠 The N4PD assay enables simultaneous measurement of NfL, GFAP, UCH-L1, and brain-derived Tau (BD-Tau) in both blood and cerebrospinal fluid (CSF). These four biomarkers are crucial in understanding a wide range of neurodegenerative conditions and brain injuries. Whether research focuses on a single neurology biomarker or explores the complex interactions of multiple markers, the Simoa® N4PD Advantage PLUS assay offers unmatched sensitivity, efficiency, and automated precision. Explore our flyer to uncover how the Simoa® N4PD Advantage PLUS is propelling research. https://bit.ly/3WMwwbk #Neurology #Biomarkers #Neurodegeneration #BDTau
To view or add a comment, sign in
-
developing new products and solutions is what scientists expect from a leading company and at #Quanterix this is our daily goal and our mindset for the future… stay tuned….mich more is yet to come… #SIMOA #biomarkers #neurology #oncology #development #research #IVD #diagnosticskit #neurodisease #improvment #alzheimerdisease #parkinsondisease #kits #earlydetection #diagnosis #clinicaldiagnosis #neurodegeneration #mentalhealth #mentaldisorder
Simoa® Neurology 4-Plex D (N4PD) Advantage PLUS Assay is empowering breakthroughs in neurology research 🧠 The N4PD assay enables simultaneous measurement of NfL, GFAP, UCH-L1, and brain-derived Tau (BD-Tau) in both blood and cerebrospinal fluid (CSF). These four biomarkers are crucial in understanding a wide range of neurodegenerative conditions and brain injuries. Whether research focuses on a single neurology biomarker or explores the complex interactions of multiple markers, the Simoa® N4PD Advantage PLUS assay offers unmatched sensitivity, efficiency, and automated precision. Explore our flyer to uncover how the Simoa® N4PD Advantage PLUS is propelling research. https://bit.ly/3WMwwbk #Neurology #Biomarkers #Neurodegeneration #BDTau
To view or add a comment, sign in
-
Great timing for a a deeper dive into the role of precision medicine in neurological disease. The FDA has recently released a guidance document about diagnostic criteria, clinical staging and the selection of appropriate outcome measures, for the early stages of Alzheimer’s Disease. To discover more how biomarker testing is shaping the neurology space read the blow here below! #precisionmedicine #biomarkers
How can precision medicine transform neurological care? Dive into the latest insights on advancements, challenges, and opportunities in the field. Genetic studies have unveiled critical pathways in neurological diseases, paving the way for personalized diagnosis and targeted therapy. From Alzheimer's to Parkinson's, precision medicine offers tailored approaches for better patient outcomes. Discover how biomarker testing, equitable access, and cross-functional collaboration are shaping the future of neurology. Read the full article here https://lnkd.in/dbBgwu9b #PrecisionMedicine #Neurology #HealthcareInnovation Ying Liu
To view or add a comment, sign in
-
🧬 Participating in clinical research here isn't just about advancing science- it's about offering hope and empowerment to patients facing challenging medical conditions. In the field of neurology, every study we conduct is a step closer to breakthrough treatments and improved quality of life. MSB Clinical Research Center is currently conducting two clinical trials with novel immunotherapeutics for the treatment of myasthenia gravis, with leading enrollment numbers globally. #neurology #clinicalresearch #MSBCRC #MyastheniaGravis #immunotherapeutics
To view or add a comment, sign in
-
Great article on the advancements of #precisionmedicine outside of oncology!
How can precision medicine transform neurological care? Dive into the latest insights on advancements, challenges, and opportunities in the field. Genetic studies have unveiled critical pathways in neurological diseases, paving the way for personalized diagnosis and targeted therapy. From Alzheimer's to Parkinson's, precision medicine offers tailored approaches for better patient outcomes. Discover how biomarker testing, equitable access, and cross-functional collaboration are shaping the future of neurology. Read the full article here https://lnkd.in/dbBgwu9b #PrecisionMedicine #Neurology #HealthcareInnovation Ying Liu
To view or add a comment, sign in
-
We’re attending the European Academy of Neurology (EAN) Congress 2024 in Helsinki, Finland, from June 29th until July 2nd. Our commitment to advancing neurological research and patient care continues as we present our latest innovations and findings. This year, we will highlight our work in Friedreich ataxia and Alzheimer's disease, as well as our increased dedication to rare diseases. Learn more: https://ow.ly/TbtX50Spw1i #EAN2024 | #Biogen | #Neurology | #Innovation | #Healthcare | #HCPs
To view or add a comment, sign in
-
Neurology Resident Physician | xNeurology Postdoctoral Fellow @ Wayne State University | xResearch Assistant @ University of Virginia | xAcademic Associate @ Pakistan Academy of Neurological Surgery
Excited to share the presentation of my research findings in multiple sclerosis (MS) related to choroid plexus volume at the American Academy of Neurology (AAN) 2024 conference in Denver, CO. My two other posters (not displayed in this post), "The Effects of Smoking on Retinal Layer Thickness in Relapsing Remitting Multiple Sclerosis Patients Using Optical Coherence Tomography" and "The Relationship Between Clinical Hand Dexterity and Diffusion Tensor Imaging Metrics in White Matter tracts of Patients with Multiple Sclerosis" were also presented at this conference. I'm glad to see the impactful translation of our MRI and OCT clinical trials conducted at the MS Center at Wayne State University in the Department of Neurology! These trials represent a significant step forward in our efforts to advance MS research and improve patient care. Recent research suggests that changes in choroid plexus volume may be associated with MS pathology. Alterations in the volume of the choroid plexus could potentially impact the production and circulation of CSF, which in turn may influence the immune response and inflammation characteristic of MS. Understanding these volume disparities in the choroid plexus between different racial cohorts could offer valuable insights into the mechanisms underlying MS progression and its potential disparities among diverse populations. #AAN #neurology #multiplesclerosis
To view or add a comment, sign in
16,680 followers